GlassScriptPhysician profile
David C Kunkel
NPI 1902056245
$286,941.81
in general payments reported to CMS, 2019-2025
21 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,850 · 2021: $25K · 2022: $26K · 2023: $56K · 2024: $75K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $198K · Travel and Lodging: $15K · Food and Beverage: $5,624 · Consulting Fee: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $198,106.00 |
| Travel and Lodging | $14,878.42 |
| Food and Beverage | $5,624.29 |
| Consulting Fee | $1,389.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $99,067.07 | 2022-2025 | Dupixent |
| Genzyme Corporation | $66,022.46 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $59,831.73 | 2024-2025 | Voquezna |
| Pfizer INC. | $22,437.21 | 2021-2024 | |
| Evoke Pharma, INC. | $16,021.29 | 2022-2024 | |
| Shire North American Group INC | $11,032.56 | 2019 | |
| Ardelyx, INC. | $2,253.87 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $2,100.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,055.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,493.22 | 2019-2025 | Xifaxan, Trulance |
| Gi Supply, INC. | $1,200.00 | 2021 | |
| Mahana Therapeutics, INC. | $1,154.22 | 2022 | |
| Palette Life Sciences, INC. | $986.25 | 2019 | |
| Alfasigma USA, INC. | $750.00 | 2020 | |
| Alnylam Pharmaceuticals INC. | $124.25 | 2025 | Amvuttra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $122.00 | 2023 | Endoflip |
| Shield Therapeutics INC | $96.83 | 2023 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $83.48 | 2023 | |
| Covidien LP | $75.46 | 2019 | |
| Abbvie INC. | $34.13 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kunkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.